Cetera Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Cetera Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$593K	Buy	6,785 +4,324	+176%	+$387K	﹤0.01%	1497
2023 Q4	$237K	Buy	+2,461	New	+$218K	﹤0.01%	1555
2023 Q2	–	Sell	-2,469	Closed	-$240K	–	1666
2023 Q1	$240K	Sell	2,469 -13,131	-84%	-$1.36M	﹤0.01%	1402
2022 Q4	$1.61M	Buy	15,600 +4,166	+36%	+$391K	0.03%	508
2022 Q3	$969K	Buy	11,434 +4,682	+69%	+$417K	0.03%	548
2022 Q2	$560K	Buy	+6,752	New	+$538K	0.01%	790

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cetera Advisors's BMRN Position: Q1 2024 in Review

Cetera Advisors increased its BioMarin Pharmaceuticals (BMRN) stake by 176% in Q1 2024, buying an estimated $387K and bringing the position to 6,785 shares worth $593K. The position accounts for ﹤0.01% of the portfolio, ranked #1497.

Cetera Advisors first reported a position in BMRN in Q2 2022 and has held it in 6 quarters since. The position peaked at $1.61M in Q4 2022. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

Cetera Advisors held 6,785 shares of BioMarin Pharmaceuticals worth $593K as of Q1 2024.
Cetera Advisors bought 4,324 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $387K.
BioMarin Pharmaceuticals made up ﹤0.01% of Cetera Advisors's portfolio in Q1 2024, its #1497 holding.
Cetera Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2022 and has held it in 6 quarters since.
Cetera Advisors's BioMarin Pharmaceuticals position peaked at $1.61M in Q4 2022.
560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on Cetera Advisors's 13F filing for Q1 2024, filed 15 May 2024.